Literature DB >> 17478356

Is a placebo-controlled surgical trial an oxymoron?

Krystene Boyle1, Frances R Batzer.   

Abstract

Within the context of the new medical methodology of evidence-based medicine, the ethical issues of making the randomized, placebo-controlled, clinical trial part of the matrix of surgical procedure evaluation are discussed. Surgical trials with alternative research design less rigorous than the double-blind, placebo-controlled, randomized trial leave the alternative: implementing surgical procedures based on anecdotal evidence and weaker scientific research. The conundrum of these clinical trials, as it relates to the evaluation of surgical procedures, is that it appears to confound some of the fundamental ethical principles of beneficence and nonbeneficence. The placebo effect with surgery is so strong that "sham surgery" within the clinical trial context is essential and an appropriate component of the ethics of clinical research. A discussion of these issues is presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478356     DOI: 10.1016/j.jmig.2006.12.006

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  3 in total

1.  Understanding the placebo effect in clinical trials for postural tachycardia syndrome.

Authors:  Victor C Nwazue; Amy C Arnold; Vidya Raj; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Carlos Orozco; William D Dupont; David Robertson; Satish R Raj
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-05       Impact factor: 2.557

2.  Comparison of Solifenacin and Bilateral Apical Fixation in the Treatment of Mixed and Urgency Urinary Incontinence in Women: URGE 1 Study, A Randomized Clinical Trial.

Authors:  Sebastian Ludwig; Ingrid Becker; Peter Mallmann; Wolfram Jäger
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 3.  Adaption and application of the four phase trials to traditional chinese medicines.

Authors:  M Y Di; J L Tang
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-20       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.